Greater Cannabis Company (GCAN) Payables (2016 - 2026)
Greater Cannabis Company's (GCAN) quarterly Payables came in at $7514.0 in Q1 2026, down 93.71% year-on-year from $119401.0 in Q1 2025, and down 11.75% quarter-over-quarter from $8514.0 in Q4 2025.
Greater Cannabis Company (GCAN) Payables (2016 - 2026) Analysis & Trends
Greater Cannabis Company's Payables history runs 11 years deep, the most recent figure standing at $7514.0 for Q1 2026.
- On a quarterly basis, Payables fell 93.71% year-over-year to $7514.0 in Q1 2026; TTM through Mar 2026 was $7514.0, a 93.71% decrease from a year earlier, with the FY2025 full-year figure at $8514.0, down 95.25% from the prior year.
- Payables slipped to $7514.0 in Q1 2026 per GCAN's latest filing, from $8514.0 in the prior quarter.
- Across five years, Payables topped out at $480392.0 in Q1 2022 and bottomed at $7514.0 in Q1 2026.
- The 5-year median for Payables is $177855.0 (2024), against an average of $193510.5.
- Across the five-year window, Payables jumped 2734.84% in 2022 and tumbled 95.25% in 2025, its largest moves.
- Year by year, Payables stood at $259688.0 in 2022, then sank by 31.64% to $177531.0 in 2023, then climbed by 1.01% to $179316.0 in 2024, then tumbled by 95.25% to $8514.0 in 2025, then slipped by 11.75% to $7514.0 in 2026.
- Per Business Quant, the three latest GCAN Payables figures stand at $7514.0 (Q1 2026), $8514.0 (Q4 2025), and $22624.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 4.96 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 2.60 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 731.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.13 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 498.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 8.82 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.75 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 773.00 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 372.00 Mn |
| 10 | Greater Cannabis Company | 292,929.85 | 292,929.85 | - | 7,514.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,514.00 |
| Dec 31, 2025 | 8,514.00 |
| Sep 30, 2025 | 22,624.00 |
| Jun 30, 2025 | 20,950.00 |
| Mar 31, 2025 | 119,401.00 |
| Dec 31, 2024 | 179,316.00 |
| Sep 30, 2024 | 177,855.00 |
| Jun 30, 2024 | 176,696.00 |
| Mar 31, 2024 | 177,696.00 |
| Dec 31, 2023 | 177,531.00 |
| Sep 30, 2023 | 210,777.00 |
| Jun 30, 2023 | 248,777.00 |
| Mar 31, 2023 | 249,430.00 |
| Dec 31, 2022 | 259,688.00 |
| Sep 30, 2022 | 321,734.00 |
| Jun 30, 2022 | 450,783.00 |
| Mar 31, 2022 | 480,392.00 |
| Dec 31, 2021 | 380,800.00 |
| Sep 30, 2021 | 307,198.00 |
| Jun 30, 2021 | 196,219.00 |